PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 134 filers reported holding PARATEK PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $4,000 | -50.0% | 756 | -61.5% | 0.00% | – |
| Q4 2019 | $8,000 | -27.3% | 1,965 | -19.5% | 0.00% | – |
| Q3 2019 | $11,000 | +10.0% | 2,440 | -2.3% | 0.00% | – |
| Q2 2019 | $10,000 | -28.6% | 2,497 | -3.6% | 0.00% | -100.0% |
| Q1 2019 | $14,000 | 0.0% | 2,590 | -2.5% | 0.00% | 0.0% |
| Q4 2018 | $14,000 | +133.3% | 2,657 | +355.0% | 0.00% | – |
| Q3 2018 | $6,000 | -71.4% | 584 | -71.6% | 0.00% | -100.0% |
| Q2 2018 | $21,000 | -30.0% | 2,058 | -11.3% | 0.00% | -50.0% |
| Q1 2018 | $30,000 | -92.0% | 2,320 | -89.0% | 0.00% | -93.3% |
| Q4 2017 | $377,000 | -27.1% | 21,048 | +2.1% | 0.03% | -36.2% |
| Q3 2017 | $517,000 | +4.4% | 20,606 | +0.3% | 0.05% | 0.0% |
| Q2 2017 | $495,000 | -25.1% | 20,537 | -40.2% | 0.05% | -25.4% |
| Q1 2017 | $661,000 | +127.9% | 34,325 | +82.2% | 0.06% | +80.0% |
| Q4 2016 | $290,000 | – | 18,839 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |